"Mutation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
| Descriptor ID |
D009154
|
| MeSH Number(s) |
G05.365.590
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mutation".
Below are MeSH descriptors whose meaning is more specific than "Mutation".
This graph shows the total number of publications written about "Mutation" by people in this website by year, and whether "Mutation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 3 | 4 |
| 2001 | 0 | 5 | 5 |
| 2002 | 1 | 2 | 3 |
| 2003 | 3 | 7 | 10 |
| 2004 | 0 | 2 | 2 |
| 2005 | 3 | 11 | 14 |
| 2006 | 5 | 6 | 11 |
| 2007 | 5 | 7 | 12 |
| 2008 | 2 | 4 | 6 |
| 2009 | 5 | 6 | 11 |
| 2010 | 1 | 11 | 12 |
| 2011 | 3 | 5 | 8 |
| 2012 | 5 | 1 | 6 |
| 2013 | 5 | 8 | 13 |
| 2014 | 2 | 7 | 9 |
| 2015 | 3 | 12 | 15 |
| 2016 | 2 | 11 | 13 |
| 2017 | 1 | 3 | 4 |
| 2018 | 4 | 6 | 10 |
| 2019 | 6 | 7 | 13 |
| 2020 | 5 | 7 | 12 |
| 2021 | 4 | 13 | 17 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mutation" by people in Profiles.
-
Clinical utility of a microRNA classifier in cytologically indeterminate thyroid nodules with RAS mutations: A multi-institutional study. Surgery. 2024 Jan; 175(1):234-240.
-
Insight and Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference on FMR1 Premutation. Cells. 2023 09 21; 12(18).
-
Screening Practices for Breast and Nonbreast Cancers in High-Risk Mutation Carriers. J Surg Res. 2023 11; 291:388-395.
-
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. J Thorac Oncol. 2023 09; 18(9):1209-1221.
-
Correlation between large FBN1 deletions and severe cardiovascular phenotype in Marfan syndrome: Analysis of two novel cases and analytical review of the literature. Mol Genet Genomic Med. 2023 07; 11(7):e2166.
-
Ligand sensitivity of type-1 inositol 1,4,5-trisphosphate receptor is enhanced by the D2594K mutation. Pflugers Arch. 2023 05; 475(5):569-581.
-
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023 01 01; 108(1):150-160.
-
De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients. Transpl Infect Dis. 2022 Dec; 24(6):e13914.
-
Reply to: Cognitive Effects of Deep Brain Stimulation in GBA-Related Parkinson's Disease. Ann Neurol. 2022 08; 92(2):345-346.
-
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022 10 01; 40(28):3289-3300.